share_log

Redhill Biopharma shares are trading lower after the company announced preliminary top-line data from the Phase 2/3 study with opaganib showed that the study did not meet its primary endpoint.

Redhill Biopharma shares are trading lower after the company announced preliminary top-line data from the Phase 2/3 study with opaganib showed that the study did not meet its primary endpoint.

Redhill Biophma的股價下跌,此前該公司宣佈,使用opaganib進行的2/3期研究的初步營收數據顯示,該研究沒有達到其主要終點。
Benzinga ·  2021/09/14 09:07

Redhill Biopharma shares are trading lower after the company announced preliminary top-line data from the Phase 2/3 study with opaganib showed that the study did not meet its primary endpoint.

Redhill Biophma的股價下跌,此前該公司宣佈,使用opaganib進行的2/3期研究的初步營收數據顯示,該研究沒有達到其主要終點。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論